
    
      This trial is a randomized Phase II study of FOLFIRINOX versus gemcitabine/abraxane in
      patients with completely resected pancreatic cancer (Stages I-III). Patients will receive
      eight weeks of chemotherapy, then 5-FU/radiation, then another 8 weeks.
    
  